Morrow G R, Lindke J, Black P M
J Pain Symptom Manage. 1991 May;6(4):215-23. doi: 10.1016/0885-3924(91)90011-r.
An algorithm based on learning theory and previous research for predicting which cancer patients would develop nausea in anticipation of chemotherapy treatments was tested. Patients with four or more of the following eight characteristics after their first treatment were predicted to develop anticipatory nausea (AN) by their fourth chemotherapy treatment: experienced nausea and/or vomiting after first treatment; nausea after treatment described as "moderate, severe, or intolerable;" vomiting after treatment described as "moderate, severe, or intolerable;" less than 50 yr of age; a susceptibilty to motion sickness; feeling warm or hot all over after treatment; sweating following treatment; feelings of generalized weakness following treatment. The characteristics significantly predicted subsequent anticipatory nausea development (p less than .01) by their fourth treatment in 355 consecutive cancer patients. Results were independent of the type of cancer being treated. The accuracy of the prediction was less specific than prior research, 34% of patients predicted to develop AN did so, compared to 16% of the total sample. Results are consistent with a learned etiology for the development of anticipatory side effects and support the importance of predictive methodologies in investigating mechanisms of anticipatory nausea development.
一种基于学习理论和先前研究的算法,用于预测哪些癌症患者在预期化疗治疗时会出现恶心,该算法经过了测试。首次治疗后具有以下八个特征中四个或更多特征的患者,预计在第四次化疗治疗时会出现预期性恶心(AN):首次治疗后经历过恶心和/或呕吐;治疗后恶心被描述为“中度、重度或无法忍受”;治疗后呕吐被描述为“中度、重度或无法忍受”;年龄小于50岁;易患晕动病;治疗后全身感到温暖或发热;治疗后出汗;治疗后感到全身虚弱。这些特征在355名连续癌症患者的第四次治疗中显著预测了随后预期性恶心的发生(p小于0.01)。结果与所治疗癌症的类型无关。预测的准确性不如先前的研究,预计会出现AN的患者中有34%确实出现了,而总样本中这一比例为16%。结果与预期性副作用发展的习得病因学一致,并支持了预测方法在研究预期性恶心发展机制中的重要性。